Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) Short Interest Down 20.0% in June
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 74,200 shares, a decline of 20.0% from the May 30th total of 92,700 shares. Currently, 2.3% of the shares of the stock are short sold. Based on an average daily volume of 346,100 shares, the days-to-cover ratio is currently 0.2 days.
An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP acquired a new stake in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned 0.95% of Diffusion Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 6.20% of the company’s stock.
DFFN stock traded up $0.02 during midday trading on Friday, hitting $2.18. 230,606 shares of the stock were exchanged, compared to its average volume of 258,769. The stock’s 50-day moving average is $3.02. The stock has a market capitalization of $7.61 million, a PE ratio of -0.35 and a beta of -0.02. Diffusion Pharmaceuticals has a fifty-two week low of $1.83 and a fifty-two week high of $11.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.35 and a current ratio of 5.35.
DFFN has been the subject of several research reports. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. HC Wainwright reaffirmed a “buy” rating on shares of Advanced Emissions Solutions in a report on Wednesday, March 20th.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.